Qualigen Therapeutics Statistics
Total Valuation
QLGN has a market cap or net worth of $5.77 million. The enterprise value is $4.60 million.
Important Dates
The next estimated earnings date is Wednesday, August 13, 2025, after market close.
| Earnings Date | Aug 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
QLGN has 1.64 million shares outstanding. The number of shares has increased by 256.41% in one year.
| Current Share Class | 1.64M |
| Shares Outstanding | 1.64M |
| Shares Change (YoY) | +256.41% |
| Shares Change (QoQ) | +102.56% |
| Owned by Insiders (%) | 0.03% |
| Owned by Institutions (%) | 0.86% |
| Float | 1.64M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.15 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.33
| Current Ratio | 2.33 |
| Quick Ratio | 1.59 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -5.94 |
Financial Efficiency
Return on equity (ROE) is -2,140.55% and return on invested capital (ROIC) is -360.17%.
| Return on Equity (ROE) | -2,140.55% |
| Return on Assets (ROA) | -100.48% |
| Return on Invested Capital (ROIC) | -360.17% |
| Return on Capital Employed (ROCE) | -201.63% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.59M |
| Employee Count | 4 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, QLGN has paid $6,334 in taxes.
| Income Tax | 6,334 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -83.74% in the last 52 weeks. The beta is 0.03, so QLGN's price volatility has been lower than the market average.
| Beta (5Y) | 0.03 |
| 52-Week Price Change | -83.74% |
| 50-Day Moving Average | 3.64 |
| 200-Day Moving Average | 4.27 |
| Relative Strength Index (RSI) | 49.72 |
| Average Volume (20 Days) | 19,372 |
Short Selling Information
The latest short interest is 27,135, so 1.66% of the outstanding shares have been sold short.
| Short Interest | 27,135 |
| Short Previous Month | 27,806 |
| Short % of Shares Out | 1.66% |
| Short % of Float | 1.66% |
| Short Ratio (days to cover) | 3.08 |
Income Statement
| Revenue | n/a |
| Gross Profit | -24,681 |
| Operating Income | -5.40M |
| Pretax Income | -11.64M |
| Net Income | -6.35M |
| EBITDA | -5.40M |
| EBIT | -5.40M |
| Earnings Per Share (EPS) | -$17.55 |
Full Income StatementBalance Sheet
The company has $1.17 million in cash and n/a in debt, giving a net cash position of $1.17 million or $0.72 per share.
| Cash & Cash Equivalents | 1.17M |
| Total Debt | n/a |
| Net Cash | 1.17M |
| Net Cash Per Share | $0.72 |
| Equity (Book Value) | 2.68M |
| Book Value Per Share | -4.12 |
| Working Capital | 2.68M |
Full Balance SheetCash Flow
| Operating Cash Flow | -6.33M |
| Capital Expenditures | n/a |
| Free Cash Flow | -6.33M |
| FCF Per Share | -$3.87 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
